CDCP1 and cancer: We observed enhancement of lymphocyte-mediated killing of cancer cells by a mAb against CD318, a CD6 ligand, which may represent a combination of nonspecific antibody-dependent cellular cytotoxicity and blockade of negative signals conveyed to lymphocytes from cancer cells arising from engagement of CD6 by CD318.